PK and Safety After C-Section
A Phase 2, Open-Label Study of the Pharmacokinetics and Safety of HTX-011 Administered Postpartum to Women Undergoing a Planned Caesarean Section
The main goal of the study was to measure the amount of the active ingredients and other components of HTX-011 in plasma and expressed breast milk over time following postpartum administration in women undergoing a planned C-section. The study also looked at the safety of HTX-011 in these women.
調査の概要
研究の種類
入学 (実際)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
Alabama
-
Sheffield、Alabama、アメリカ、35660
- Helen Keller Hospital
-
-
California
-
San Diego、California、アメリカ、92123
- Sharp Mary Birch Hospital for Women and Newborns
-
-
North Carolina
-
Durham、North Carolina、アメリカ、27710
- Duke University Medical Center
-
-
Pennsylvania
-
Pittsburgh、Pennsylvania、アメリカ、15213
- UPMC Magee-Womens Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Is expected, at the time of Screening visit, to deliver a single neonate.
- Is scheduled to undergo a planned C-section surgery with a low transverse skin incision (eg, Pfannenstiel).
- Has American Society of Anesthesiologists (ASA) Physical Status of I, II, or III.
- Agrees to practice abstinence or use double-barrier contraception in the event of sexual activity and commits to the use of an acceptable form of birth control for 30 days after HTX-011 administration.
- Agrees to refrain from the use of breast milk from this pregnancy in any manner.
Exclusion Criteria:
- Has planned to breastfeed her neonate at any time during the 28-day period after HTX-011 administration.
- Has had a prior full-term pregnancy with unsuccessful breast milk expression.
- Has a planned concurrent surgical procedure.
- Has a contraindication or a known or suspected history of hypersensitivity or clinically significant idiosyncratic reaction to required study medications.
- Has been administered bupivacaine within 5 days prior to the scheduled surgery.
- Has been administered any local anesthetic within 72 hours prior to the scheduled surgery.
- Has been administered systemic steroids within 5 half-lives or 10 days prior to administration of study drug.
- Has initiated treatment with study medications within 1 month prior to study drug administration that can impact pain control.
- Has taken any NSAIDs within least 10 days prior to the scheduled surgery.
- Has current significant placental abnormality/complications including, but not limited to, placenta previa or placenta accreta.
- Has a medical condition such that, in the opinion of the Investigator, participating in the study would pose a health risk to the subject or confound the postoperative assessments.
- Has uncontrolled anxiety, psychiatric, or neurological disorder.
- Had a malignancy in the last year, with the exception of nonmetastatic basal cell or squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix.
- Has a known or suspected history of drug abuse, a positive drug screen on the day of surgery, or a recent history of alcohol abuse.
- Previously participated in an HTX-011 study.
- Received an investigational product or device in a clinical trial within 30 days or within 5 elimination half-lives.
- Weight is <50 kg at the time of Screening visit.
- In the Investigator's judgment, subject is likely to have been morbidly obese prior to her pregnancy.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:非ランダム化
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:HTX-011 300 mg/9 mg
HTX-011 (bupivacaine/meloxicam) 300 mg/9 mg via instillation |
bupivacaine/meloxicam extended-release solution for instillation use, supplied in commercially available ZYNRELEF kits
他の名前:
ZYNRELEF kits include sterile, individually packaged components for administration, including vented vial spikes, Luer lock syringes, custom Luer lock applicators, and syringe tip caps. |
|
実験的:HTX-011 400 mg/12 mg + MMA
HTX-011 (bupivacaine/meloxicam) 400 mg/12 mg via instillation + oral (PO) non-opioid multimodal analgesic (MMA) regimen |
bupivacaine/meloxicam extended-release solution for instillation use, supplied in commercially available ZYNRELEF kits
他の名前:
ZYNRELEF kits include sterile, individually packaged components for administration, including vented vial spikes, Luer lock syringes, custom Luer lock applicators, and syringe tip caps. PO ibuprofen 400 mg every 6 hours (q6h), alternating with PO acetaminophen 975 mg to 1 g q6h, alternating the 2 medications so that an analgesic was taken approximately every 3 hours (q3h) while the subject was awake
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Bupivacaine Plasma Cmax
時間枠:Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
|
Maximum plasma concentration of bupivacaine |
Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
|
|
Bupivacaine Plasma Tmax
時間枠:Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
|
Time to maximum concentration of bupivacaine in plasma |
Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
|
|
Bupivacaine Plasma t1/2
時間枠:Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
|
Half life of bupivacaine in plasma |
Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
|
|
Bupivacaine Plasma AUCinf
時間枠:Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
|
Area under the bupivacaine plasma concentration-time curve from Time 0 extrapolated to infinity |
Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
|
|
Bupivacaine Breast Milk Cmax
時間枠:Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
|
Maximum concentration of bupivacaine in breast milk |
Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
|
|
Bupivacaine Breast Milk Tmax
時間枠:Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
|
Time to maximum concentration of bupivacaine in breast milk |
Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
|
|
Bupivacaine Breast Milk AUClast
時間枠:Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
|
Area under the bupivacaine breast milk concentration-time curve from Time 0 to time of last quantifiable concentration |
Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
|
|
Meloxicam Plasma Cmax
時間枠:Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
|
Maximum plasma concentrations of meloxicam |
Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
|
|
Meloxicam Plasma Tmax
時間枠:Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
|
Time to maximum meloxicam plasma concentration in plasma |
Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
|
|
Meloxicam Plasma t1/2
時間枠:Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
|
Half-life of meloxicam in plasma |
Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
|
|
Meloxicam Plasma AUCinf
時間枠:Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
|
Area under the meloxicam plasma concentration-time curve from Time 0 extrapolated to infinity |
Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
|
|
Meloxicam Breast Milk Cmax
時間枠:Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
|
Maximum concentration of meloxicam in breast milk |
Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
|
|
Meloxicam Breast Milk Tmax
時間枠:Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
|
Time to maximum meloxicam concentration in breast milk |
Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
|
|
Meloxicam Breast Milk AUClast
時間枠:Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
|
Area under the meloxicam breast milk concentration-time curve from Time 0 to time of last quantifiable concentration |
Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。